Thermo Fisher Scientific Inc. $TMO Stock Position Trimmed by Douglas Lane & Associates LLC

Posted by Stanley Muller on Oct 9th, 2026

Douglas Lane & Associates LLC lowered its position in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 2.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 216,638 shares of the medical research company’s stock after selling 5,041 shares during the quarter. Thermo Fisher Scientific accounts for 1.8% of Douglas Lane & Associates LLC’s investment portfolio, making the stock its 11th biggest position. Douglas Lane & Associates LLC owned 0.06% of Thermo Fisher Scientific worth $146,242,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of TMO. Dakota Community Bank & Trust NA increased its holdings in shares of Thermo Fisher Scientific by 53.8% in the 3rd quarter. Dakota Community Bank & Trust NA now owns 203 shares of the medical research company’s stock valued at $137,000 after acquiring an additional 71 shares during the last quarter. Graves Light Lenhart Wealth Inc. bought a new stake in shares of Thermo Fisher Scientific during the third quarter valued at approximately $208,000. Chapin Davis Inc. acquired a new position in Thermo Fisher Scientific during the 3rd quarter worth $209,000. Inspirion Wealth Advisors LLC acquired a new stake in Thermo Fisher Scientific in the third quarter worth about $236,000. Finally, Monument Capital Management lifted its stake in shares of Thermo Fisher Scientific by 20.8% in the 3rd quarter. Monument Capital Management now owns 1,016 shares of the medical research company’s stock worth $686,000 after acquiring an additional 175 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Buying and Selling

In related news, CAO Joseph Holmes sold 420 shares of the stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the completion of the transaction, the chief accounting officer directly owned 2,966 shares of the company’s stock, valued at approximately $1,734,546.46. This represents a 12.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Lisa Britt sold 11,440 shares of the business’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the transaction, the vice president owned 14,784 shares in the company, valued at $9,064,366.08. This represents a 43.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 73,768 shares of company stock worth $44,122,820 in the last three months. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Trading Up 1.1%

Shares of TMO stock traded up $7.33 on Friday, reaching $659.31. 482,660 shares of the stock were exchanged, compared to its average volume of 2,244,217. Thermo Fisher Scientific Inc. has a one year low of $435.27 and a one year high of $694.33. The stock has a 50 day moving average price of $625.73 and a 200 day moving average price of $540.54. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The stock has a market cap of $243.78 billion, a PE ratio of 35.44, a P/E/G ratio of 2.77 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last posted its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. During the same period last year, the business posted $4.28 earnings per share. The business’s revenue for the quarter was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Piper Sandler initiated coverage on shares of Thermo Fisher Scientific in a research report on Wednesday, September 9th. They set an “overweight” rating for the company. Royal Bank Of Canada raised their price target on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a “sector perform” rating in a report on Friday, July 24th. Stifel Nicolaus set a $650.00 price objective on Thermo Fisher Scientific in a report on Wednesday, August 5th. UBS Group raised Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and raised their price objective for the company from $540.00 to $730.00 in a research note on Tuesday, September 8th. Finally, Scotiabank initiated coverage on Thermo Fisher Scientific in a research note on Wednesday, September 9th. They issued an “outperform” rating on the stock. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $634.86.

View Our Latest Report on TMO

Thermo Fisher Scientific Company Profile

(Free Report)

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company’s portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.